<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01373281</url>
  </required_header>
  <id_info>
    <org_study_id>CYD14</org_study_id>
    <secondary_id>UTN: U1111-1116-4957</secondary_id>
    <secondary_id>2014-001708-24</secondary_id>
    <nct_id>NCT01373281</nct_id>
  </id_info>
  <brief_title>Study of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia</brief_title>
  <official_title>Efficacy and Safety of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the trial was to assess the efficacy of the CYD dengue vaccine in preventing
      symptomatic, virologically-confirmed dengue (VCD) cases.

      Primary Objective:

      To assess the efficacy of CYD dengue vaccine after 3 vaccinations at 0, 6, and 12 months in
      preventing symptomatic VCD cases, regardless of the severity, due to any of the four
      serotypes in children aged 2 to 14 years at the time of inclusion.

      Secondary Objectives:

        -  To describe the efficacy of CYD dengue vaccine in preventing symptomatic VCD cases after
           the third dose to the end of the Active Phase, after at least 1 dose, and after 2 doses.

        -  To describe the occurrence of serious adverse events (SAEs), including SAEs of special
           interest in all participants throughout the trial period.

        -  To describe the occurrence of hospitalized virologically-confirmed dengue (VCD) cases
           and the occurrence of severe (clinically-severe or as per World Health Organization
           (WHO) criteria) VCD cases, throughout the Surveillance Expansion period (SEP) and
           throughout the trial (from Day 0 to the end of the study).

        -  To describe the antibody response to each dengue serotype after Dose 2, after Dose 3,
           and 1 and 5 years after Dose 3.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants were randomized to either receive 3 injections of CYD dengue vaccine or a
      placebo at 0, 6, and 12 months.

      A subset of participants from each country were also evaluated for reactogenicity and
      immunogenicity.

      Participants who consented to participate in the SEP were actively followed for dengue case
      detection (i.e. at least weekly contact and capturing any acute febrile illness, not just
      hospitalized febrile cases, as in the Active Phase). The SEP was designed to maximize the
      detection of symptomatic confirmed dengue (hospitalized or not) in order to describe CYD
      dengue vaccine efficacy and safety in preventing symptomatic dengue. Participants who
      declined participating in the SEP continued surveillance as in the Hospital Phase until trial
      completion.

      Symptomatic VCD cases occurring more than (&gt;) 28 days after dose 3 (during the Active Phase)
      are defined as:

        -  Acute febrile illness (i.e. temperature &gt;=38 C on at least 2 consecutive days)

        -  Virologically confirmed by dengue Reverse Transcriptase-Polymerase Chain Reaction
           (RT-PCR) and/or dengue non-structural (NS)1 enzyme-linked immunosorbent assay (ELISA) Ag
           test

           1997 WHO Classification Dengue hemorrhagic fever (DHF) cases were defined as per the
           1997 WHO criteria of clinical manifestations; a) Fever: acute onset, high (&gt;= 38°C) and
           continuous, lasting 2 to 7 days and (b) any of the pre-listed hemorrhagic manifestations
           and laboratory findings of thrombocytopenia (platelet&lt;=100 x 109/L) and plasma leakage
           as shown by hemoconcentation (hematocrit increased by 20 percent [%] or more) or pleural
           effusion (seen on chest X-ray [CXR]) and/or ascites and/or hypoaluminemia. The first two
           clinical criteria plus thrombocytopenia and signs of plasma leakage are enough to
           establish a clinical diagnosis of DHF.

      DHF was graded as follows:- Grade I: Fever accompanied by non-specific constitutional
      symptoms; the only hemorrhagic manifestation is a positive tourniquet test; Grade II:
      Spontaneous bleeding in addition to the manifestations of Grade I participants, usually in
      the form of skin and/or other hemorrhages; Grade III: Circulatory failure manifested by rapid
      and weak pulse, narrowing of pulse pressure (20 mmHg or less) or hypotension, with the
      presence of cold clammy skin and restlessness; and Grade IV: Profound shock with undetectable
      blood pressure and pulse.

      Independent Data Monitoring Committee (IDMC) severity criteria The severity of VCD cases was
      assessed by an Independent IDMC using pre-defined standardized criteria. Following
      manifestations of severity were considered in all suspected VCD cases; 1) Platelet count &lt;=
      100000μl and bleeding (tourniquet, petechiae or any bleeding) plus plasma leakage (effusion
      on CXR OR clinically apparent ascites or hematocrit &gt;=20% above baseline recovery level) 2)
      Shock (pulse pressure &lt;= 20 mmHg in a child, or hypotension [&lt;= 90 mmHg] with tachycardia,
      weak pulse and poor perfusion) 3) Bleeding requiring blood transfusion 4) Encephalopathy i.e.
      Unconsciousness or poor conscious state or convulsionsfitting not attributable to simple
      febrile convulsion as defined in the guidelines for definition and collection of febrile
      convulsions or focal neurological signs. Poor conscious state or unconsciousness must be
      supported by Glasgow Coma Scale (GCS) score. 5) Liver impairment (aspartate aminotransferase
      [AST] &gt;1000IU/L or prothrombin time [PT] International normalized ratio [INR] &gt;1.5) excluding
      other causes of viral hepatitis 6) Impaired kidney function (serum creatinine ≥ 1.5 mg/dL) 7)
      Myocarditis, pericarditis or clinical heart failure supported by CXR, echocardiography,
      electrocardiogram (ECG) or cardiac enzymes.

      The designation of such cases as severe or otherwise will be made on a case by case basis by
      the IDMC.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 3, 2011</start_date>
  <completion_date type="Actual">November 21, 2017</completion_date>
  <primary_completion_date type="Actual">August 1, 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Symptomatic Virologically Confirmed Dengue (VCD) Cases Due to Any Serotype During the Active Phase Post-dose 3 Following Injection (Inj.) With Either CYD Dengue Vaccine or a Placebo</measure>
    <time_frame>28 days and up to 13 months post-dose 3</time_frame>
    <description>Symptomatic VCD cases were defined as occurrence of acute febrile illness (temperature &gt;=38°C on at least 2 consecutive days) and confirmation of dengue virus infection by dengue reverse transcriptase polymerase chain reaction and/or dengue NS protein 1 antigen enzyme-linked immunosorbent assay. Vaccine efficacy was defined as 1 minus the ratio of density incidence due to any serotype after at least 1 dose in the CYD Dengue Vaccine Group over the density incidence of the Placebo Vaccine Group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers of Antibodies Against Each Serotype With the Parental Dengue Virus Strain Before and Following Injection With Either CYD Dengue Tetravalent Vaccine or a Placebo</measure>
    <time_frame>Pre-injection 1, 28 days post Injections 2 and 3, 13 months (Visit 07) and 60 months (Visit 12) post-injection 3</time_frame>
    <description>Geometric mean titers against each of the 4 serotypes of dengue virus strains were assessed using the plaque reduction neutralization test (PRNT) in a pre-defined subset of participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Antibody Titers &gt;= 10 1/Dilution (1/Dil) Against Each Dengue Virus Serotype Strain Before and Following Inj. With CYD Dengue Vaccine or Placebo</measure>
    <time_frame>Pre-injection 1, 28 days post Injections 2 and 3, 13 months (V 07) and 60 months (V 12) post-injection 3</time_frame>
    <description>Percentage of participants with antibody titers &gt;= 10 (1/Dil) against each serotypes of the dengue virus strains were assessed using PRNT in a pre-defined subset of participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Symptomatic VCD Cases Due to Any Serotype Occurring 28 Days Post-dose 1 Following Injection With Either CYD Dengue Vaccine or a Placebo</measure>
    <time_frame>28 days post-injection 1 and up to 13 months post-injection 3</time_frame>
    <description>Symptomatic VCD cases were defined as occurrence of acute febrile illness (temperature &gt;= 38°C on at least 2 consecutive days) and confirmation of dengue virus infection by dengue reverse transcriptase polymerase chain reaction and/or dengue NS1 enzyme-linked immunosorbent assay. Vaccine efficacy was defined as 1 minus the ratio of density incidence due to any serotype after at least 1 dose in the CYD Dengue Vaccine Group over the density incidence of the Placebo Vaccine Group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Symptomatic VCD Cases Due to Any Serotype 28 Days Post-dose 2 Following Injection With Either CYD Dengue Vaccine or a Placebo</measure>
    <time_frame>28 days post-injection 2 and up to 13 months post-injection 3</time_frame>
    <description>Symptomatic VCD cases were defined as occurrence of acute febrile illness (temperature &gt;= 38°C on at least 2 consecutive days) and confirmation of dengue virus infection by dengue reverse transcriptase polymerase chain reaction and/or dengue NS1 enzyme-linked immunosorbent assay. Vaccine efficacy was defined as 1 minus the ratio of density incidence due to any serotype after at least 1 dose in the CYD Dengue Vaccine Group over the density incidence of the Placebo Vaccine Group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Symptomatic VCD Cases Due to Any Serotype During the Active Phase in Either CYD Dengue Vaccine or Placebo Group</measure>
    <time_frame>Day 0 up to 13 months post-injection 3</time_frame>
    <description>Symptomatic VCD cases were defined as occurrence of acute febrile illness (temperature &gt;=38°C on at least 2 consecutive days) and confirmation of dengue virus infection by dengue reverse transcriptase polymerase chain reaction and/or dengue NS1 enzyme-linked immunosorbent assay. Vaccine efficacy was defined as 1 minus the ratio of density incidence due to any serotype after at least 1 dose in the CYD Dengue Vaccine Group over the density incidence of the Placebo Vaccine Group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Symptomatic VCD Cases Meeting 1997 WHO Criteria Throughout the Trial Due to Any Serotype Following Injection With Either CYD Dengue Vaccine or a Placebo</measure>
    <time_frame>Day 0 to the end of study (up to 72 months)</time_frame>
    <description>Dengue hemorrhagic fever cases were defined as number of participants with at least one symptomatic VCD episode meeting the 1997 WHO criteria.
(a) Fever: acute onset, high (&gt;= 38°C) and continuous, lasting 2 to 7 days and (b) any of the pre-listed hemorrhagic manifestations and laboratory findings of thrombocytopenia (platelet &lt;=100 x 109/L) and plasma leakage as shown by hemoconcentation (hematocrit increased by 20% or more) or pleural effusion (seen on CXR) and/or ascites and/or hypoaluminemia. The first two clinical criteria plus thrombocytopenia and signs of plasma leakage are enough to establish a clinical diagnosis of DHF. Dengue hemorrhagic fever was graded as follows: Grade I: Fever accompanied by non-specific constitutional symptoms; the only hemorrhagic manifestation is a positive tourniquet test; Grade II: Spontaneous bleeding in addition to the manifestations of Grade I participants, usually in the form of skin and/or other hemorrhage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Symptomatic VCD Cases Meeting 1997 WHO Criteria During the Surveillance Expansion Period Due to Any Serotype Following Inj. With Either CYD Dengue Vaccine or a Placebo</measure>
    <time_frame>From consent to participate int the Surveillance Expansion Period to 60 months post-injection 3 (up to Month 72)</time_frame>
    <description>The 1997 WHO criteria are: a) Fever: acute onset, high (&gt;= 38°C) and continuous, for 2 to 7 days and (b) any of the following: thrombocytopenia (platelet &lt;=100 x 109/L) and plasma leakage as shown by hematocrit increased by 20% or more or pleural effusion and/or ascites and/or hypoaluminemia. The first two clinical criteria plus thrombocytopenia and signs of plasma leakage are enough to establish diagnosis of DHF. Dengue hemorrhagic fever was graded as follows:Grade I: Fever accompanied by non-specific constitutional symptoms; the only hemorrhagic manifestation is a positive tourniquet test; Grade II: Spontaneous bleeding in addition to the manifestations of Grade I participant,usually in the form of skin and/or other hemorrhages; Grade III: Circulatory failure manifested by rapid and weak pulse, narrowing of pulse pressure (20 mmHg or less) or hypotension, with the presence of cold clammy skin and restlessness; and Grade IV: Profound shock with undetectable blood pressure and pulse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Clinically Severe VCD Cases Throughout the Trial Due to Any Serotype Following Inj. With Either CYD Dengue Vaccine or a Placebo</measure>
    <time_frame>Day 0 to the end of study (up to 72 months)</time_frame>
    <description>The severity of VCD cases was assessed by an IDMC based on a medical review of cases and any of the following criteria:1) Platelet count &lt;=100000 μl and bleeding (tourniquet, petechiae or any bleeding) plus plasma leakage 2) Shock (pulse pressure &lt;= 20 mmHg in a child, or hypotension [&lt;= 90 mmHg] with tachycardia, weak pulse and poor perfusion) 3) Bleeding requiring blood transfusion 4) Encephalopathy i.e. Unconsciousness or poor conscious state or fitting not attributable to simple febrile convulsion or focal neurological signs. Poor conscious state or unconsciousness must be supported by GCS score 5) Liver impairment (AST &gt;1000 IU/L or PT INR &gt;1.5) excluding other causes of viral hepatitis 6) Impaired kidney function (serum creatinine &gt;= 1.5 mg/dL) 7) Myocarditis, pericarditis or clinical heart failure supported by CXR, echocardiography, ECG or cardiac enzymes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Clinically Severe VCD Cases During the Surveillance Expansion Period Due to Any Serotype Following Inj. With Either CYD Dengue Vaccine or a Placebo</measure>
    <time_frame>From consent to participate in the Surveillance Expansion Period to 60 months post-injection 3 (up to Month 72)</time_frame>
    <description>The severity of VCD cases was assessed by an IDMC based on a medical review of cases and any of the following criteria:1) Platelet count &lt;=100000μl and bleeding (tourniquet, petechiae or any bleeding) plus plasma leakage 2) Shock (pulse pressure &lt;= 20mmHg in a child, or hypotension [&lt;= 90 mmHg] with tachycardia, weak pulse and poor perfusion) 3) Bleeding requiring blood transfusion 4) Encephalopathy i.e. Unconsciousness or poor conscious state or fitting not attributable to simple febrile convulsion or focal neurological signs. Poor conscious state or unconsciousness must be supported by GCS score 5) Liver impairment (AST &gt;1000 IU/L or PT INR &gt;1.5) excluding other causes of viral hepatitis 6) Impaired kidney function (serum creatinine &gt;= 1.5 mg/dL) 7) Myocarditis, pericarditis or clinical heart failure supported by CXR, echocardiography, ECG or cardiac enzymes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Solicited Injection Site Reactions Following Any and Each Inj. With Either CYD Dengue Vaccine or a Placebo</measure>
    <time_frame>Within 7 days after injection</time_frame>
    <description>Solicited injection site reactions: Pain, Erythema, and Swelling. Grade 3 reactions (2-11 years): Pain, Incapacitating, unable to perform usual activities; Erythema and Swelling, &gt;= 50 mm. Grade 3 Solicited injection site reactions (12-14 years): Pain, Significant, prevents daily activity; Erythema and Swelling, &gt;100 mm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Systemic Reactions Following Any and Each Inj. With Either CYD Dengue Vaccine or a Placebo</measure>
    <time_frame>Within 14 days after injection</time_frame>
    <description>Solicited systemic reactions: Fever (Temperature), Headache, Malaise, Myalgia, and Asthenia. Grade 3 reactions: Fever, &gt;= 39°C; Headache, Malaise, Myalgia, and Asthenia, Significant, prevents daily activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Hospitalized VCD Cases Throughout the Trial Due to Any Serotype Following Injection With Either CYD Dengue Vaccine or a Placebo</measure>
    <time_frame>Day 0 to the end of study (up to 72 months)</time_frame>
    <description>Hospitalized VCD cases were defined as VCD confirmed by dengue RT-PCR and/or dengue NS1 ELISA in participants with acute febrile illness (temperature &gt;=38°C on at least 2 consecutive days) requiring hospitalization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Hospitalized VCD Cases During the Surveillance Expansion Period Due to Any Serotype Following Injection With Either CYD Dengue Vaccine or a Placebo</measure>
    <time_frame>From consent to participate in the Surveillance Expansion Period to 60 months post-injection 3 (up to Month 72)</time_frame>
    <description>Hospitalized VCD cases were defined as VCD confirmed by dengue RT-PCR and/or dengue NS1 ELISA in participants with acute febrile illness (temperature &gt;= 38°C on at least 2 consecutive days) requiring hospitalization.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10275</enrollment>
  <condition>Dengue</condition>
  <condition>Dengue Fever</condition>
  <condition>Dengue Hemorrhagic Fever</condition>
  <arm_group>
    <arm_group_label>Dengue Vaccine Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants were to receive CYD dengue vaccine at 0, 6, and 12 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants were to receive a placebo vaccine at 0, 6, and 12 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Live, attenuated, dengue serotype 1, 2, 3, 4 virus</intervention_name>
    <description>0.5 mL, Subcutaneous</description>
    <arm_group_label>Dengue Vaccine Group</arm_group_label>
    <other_name>CYD Dengue Vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo: Sodium chloride (NaCl) 0.9%</intervention_name>
    <description>0.5 mL, Subcutaneous</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 2 to 14 years on the day of inclusion and resident of the site zone

          -  Participant was in good health, based on medical history and physical examination

          -  Assent form or informed consent form has been signed and dated by the participant
             (based on local regulations), and informed consent form has been signed and dated by
             the parent(s) or another legally acceptable representative (and by an independent
             witness if required by local regulations)

          -  Participant attended all scheduled visits and to comply with all trial procedures.

        Exclusion Criteria:

          -  Participant was pregnant, or lactating, or was of childbearing potential (to be
             considered of non-childbearing potential, a female must be pre-menarche for at least 1
             year, surgically sterile, or using an effective method of contraception or abstinence
             from at least 4 weeks prior to the first vaccination until at least 4 weeks after the
             last vaccination)

          -  Participation in another clinical trial investigating a vaccine, drug, medical device,
             or a medical procedure in the 4 weeks preceding the first trial vaccination

          -  Planned participation in another clinical trial during the present trial period

          -  Self-reported or suspected congenital or acquired immunodeficiency; or receipt of
             immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within
             the preceding 6 months; or long-term systemic corticosteroids therapy (prednisone or
             equivalent for more than 2 consecutive weeks within the past 3 months)

          -  Self-reported seropositivity for Human Immunodeficiency Virus (HIV) infection

          -  Self-reported systemic hypersensitivity to any of the vaccine components, or history
             of a life-threatening reaction to the vaccine used in the trial or to a vaccine
             containing any of the same substances

          -  Chronic illness that, in the opinion of the Investigator, is at a stage where it might
             interfere with trial conduct or completion

          -  Receipt of blood or blood-derived products in the past 3 months, which might interfere
             with assessment of the immune response

          -  Planned receipt of any vaccine in the 4 weeks following any trial vaccination

          -  Deprived of freedom by administrative or court order, or in an emergency setting, or
             hospitalized involuntarily

          -  Current alcohol abuse or drug addiction that might interfere with the ability to
             comply with trial procedures

          -  Identified as a site employee of the Investigator or study center, with direct
             involvement in the proposed study or other studies under the direction of that
             Investigator or study center, as well as a family member (i.e., immediate, husband,
             wife and their children, adopted or natural) of the site employees or the
             Investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur SA</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Denpasar</city>
        <state>Bali</state>
        <zip>80114</zip>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bandung</city>
        <state>West Java</state>
        <zip>40161</zip>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jakarta</city>
        <zip>10430</zip>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kuala Lumpur</city>
        <zip>50586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pulau Pinang</city>
        <zip>10450</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cebu City</city>
        <zip>6000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Pablo City</city>
        <zip>4000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nai Muang</city>
        <state>Kamphaeng Phet Province</state>
        <zip>6200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ban Pong</city>
        <state>Ratchaburi Province</state>
        <zip>70110</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Photharam</city>
        <state>Ratchaburi Province</state>
        <zip>70120</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Long Xuyên</city>
        <state>An Giang Province</state>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mỹ Tho</city>
        <state>Tien Giang Province</state>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Indonesia</country>
    <country>Malaysia</country>
    <country>Philippines</country>
    <country>Thailand</country>
    <country>Vietnam</country>
  </location_countries>
  <results_reference>
    <citation>Capeding MR, Tran NH, Hadinegoro SR, Ismail HI, Chotpitayasunondh T, Chua MN, Luong CQ, Rusmil K, Wirawan DN, Nallusamy R, Pitisuttithum P, Thisyakorn U, Yoon IK, van der Vliet D, Langevin E, Laot T, Hutagalung Y, Frago C, Boaz M, Wartel TA, Tornieporth NG, Saville M, Bouckenooghe A; CYD14 Study Group. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet. 2014 Oct 11;384(9951):1358-65. doi: 10.1016/S0140-6736(14)61060-6. Epub 2014 Jul 10.</citation>
    <PMID>25018116</PMID>
  </results_reference>
  <results_reference>
    <citation>L'Azou M, Moureau A, Sarti E, Nealon J, Zambrano B, Wartel TA, Villar L, Capeding MR, Ochiai RL; CYD14 Primary Study Group; CYD15 Primary Study Group. Symptomatic Dengue in Children in 10 Asian and Latin American Countries. N Engl J Med. 2016 Mar 24;374(12):1155-66. doi: 10.1056/NEJMoa1503877.</citation>
    <PMID>27007959</PMID>
  </results_reference>
  <results_reference>
    <citation>Coudeville L, Baurin N, Vergu E. Estimation of parameters related to vaccine efficacy and dengue transmission from two large phase III studies. Vaccine. 2016 Dec 7;34(50):6417-6425. doi: 10.1016/j.vaccine.2015.11.023. Epub 2015 Nov 21.</citation>
    <PMID>26614588</PMID>
  </results_reference>
  <results_reference>
    <citation>Hadinegoro SR, Arredondo-García JL, Capeding MR, Deseda C, Chotpitayasunondh T, Dietze R, Muhammad Ismail HI, Reynales H, Limkittikul K, Rivera-Medina DM, Tran HN, Bouckenooghe A, Chansinghakul D, Cortés M, Fanouillere K, Forrat R, Frago C, Gailhardou S, Jackson N, Noriega F, Plennevaux E, Wartel TA, Zambrano B, Saville M; CYD-TDV Dengue Vaccine Working Group. Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease. N Engl J Med. 2015 Sep 24;373(13):1195-206. doi: 10.1056/NEJMoa1506223. Epub 2015 Jul 27.</citation>
    <PMID>26214039</PMID>
  </results_reference>
  <results_reference>
    <citation>Guy B, Jackson N. Dengue vaccine: hypotheses to understand CYD-TDV-induced protection. Nat Rev Microbiol. 2016 Jan;14(1):45-54. doi: 10.1038/nrmicro.2015.2. Epub 2015 Dec 7. Review.</citation>
    <PMID>26639777</PMID>
  </results_reference>
  <results_reference>
    <citation>Gailhardou S, Skipetrova A, Dayan GH, Jezorwski J, Saville M, Van der Vliet D, Wartel TA. Safety Overview of a Recombinant Live-Attenuated Tetravalent Dengue Vaccine: Pooled Analysis of Data from 18 Clinical Trials. PLoS Negl Trop Dis. 2016 Jul 14;10(7):e0004821. doi: 10.1371/journal.pntd.0004821. eCollection 2016 Jul.</citation>
    <PMID>27414655</PMID>
  </results_reference>
  <results_reference>
    <citation>Vigne C, Dupuy M, Richetin A, Guy B, Jackson N, Bonaparte M, Hu B, Saville M, Chansinghakul D, Noriega F, Plennevaux E. Integrated immunogenicity analysis of a tetravalent dengue vaccine up to 4 y after vaccination. Hum Vaccin Immunother. 2017 Sep 2;13(9):2004-2016. doi: 10.1080/21645515.2017.1333211. Epub 2017 Jun 9.</citation>
    <PMID>28598256</PMID>
  </results_reference>
  <results_reference>
    <citation>Guy B, Noriega F, Ochiai RL, L'azou M, Delore V, Skipetrova A, Verdier F, Coudeville L, Savarino S, Jackson N. A recombinant live attenuated tetravalent vaccine for the prevention of dengue. Expert Rev Vaccines. 2017 Jul;16(7):1-13. doi: 10.1080/14760584.2017.1335201. Epub 2017 Jun 7. Review. Erratum in: Expert Rev Vaccines. 2017 Jul;16(7):ix.</citation>
    <PMID>28590795</PMID>
  </results_reference>
  <results_reference>
    <citation>Nealon J, Taurel AF, Capeding MR, Tran NH, Hadinegoro SR, Chotpitayasunondh T, Chong CK, Wartel TA, Beucher S, Frago C, Moureau A, Simmerman M, Laot T, L'Azou M, Bouckenooghe A. Symptomatic Dengue Disease in Five Southeast Asian Countries: Epidemiological Evidence from a Dengue Vaccine Trial. PLoS Negl Trop Dis. 2016 Aug 17;10(8):e0004918. doi: 10.1371/journal.pntd.0004918. eCollection 2016 Aug.</citation>
    <PMID>27532617</PMID>
  </results_reference>
  <results_reference>
    <citation>Olivera-Botello G, Coudeville L, Fanouillere K, Guy B, Chambonneau L, Noriega F, Jackson N; CYD-TDV Vaccine Trial Group. Tetravalent Dengue Vaccine Reduces Symptomatic and Asymptomatic Dengue Virus Infections in Healthy Children and Adolescents Aged 2-16 Years in Asia and Latin America. J Infect Dis. 2016 Oct 1;214(7):994-1000. doi: 10.1093/infdis/jiw297. Epub 2016 Jul 14.</citation>
    <PMID>27418050</PMID>
  </results_reference>
  <results_reference>
    <citation>Coudeville L, Baurin N, L'Azou M, Guy B. Potential impact of dengue vaccination: Insights from two large-scale phase III trials with a tetravalent dengue vaccine. Vaccine. 2016 Dec 7;34(50):6426-6435. doi: 10.1016/j.vaccine.2016.08.050. Epub 2016 Sep 3.</citation>
    <PMID>27601343</PMID>
  </results_reference>
  <results_reference>
    <citation>Sridhar S, Luedtke A, Langevin E, Zhu M, Bonaparte M, Machabert T, Savarino S, Zambrano B, Moureau A, Khromava A, Moodie Z, Westling T, Mascareñas C, Frago C, Cortés M, Chansinghakul D, Noriega F, Bouckenooghe A, Chen J, Ng SP, Gilbert PB, Gurunathan S, DiazGranados CA. Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy. N Engl J Med. 2018 Jul 26;379(4):327-340. doi: 10.1056/NEJMoa1800820. Epub 2018 Jun 13.</citation>
    <PMID>29897841</PMID>
  </results_reference>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>June 8, 2011</study_first_submitted>
  <study_first_submitted_qc>June 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2011</study_first_posted>
  <results_first_submitted>September 15, 2015</results_first_submitted>
  <results_first_submitted_qc>October 16, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 16, 2015</results_first_posted>
  <last_update_submitted>November 21, 2018</last_update_submitted>
  <last_update_submitted_qc>November 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dengue</keyword>
  <keyword>Dengue fever</keyword>
  <keyword>Dengue Hemorrhagic Fever</keyword>
  <keyword>CYD dengue vaccine</keyword>
  <keyword>Flavivirus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dengue</mesh_term>
    <mesh_term>Hemorrhagic Fevers, Viral</mesh_term>
    <mesh_term>Severe Dengue</mesh_term>
    <mesh_term>Fever</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data (IPD) and supporting clinical documents are available for request at www.clinicalstudydatarequest.com. While making information available we continue to protect the privacy of the participants in our clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: Clinicalstudydatarequest.com/Sanofi.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study participants were enrolled from 03 June 2011 to 01 December 2011 at 9 sites in Indonesia, 5 in Malaysia, 3 in Thailand, 5 in Philippines, and 2 in Vietnam.</recruitment_details>
      <pre_assignment_details>A total of 10275 participants were enrolled; all but one met all of the inclusion criteria and none of the exclusion criteria. Three participants were not vaccinated and were excluded from the Full Analysis Set for Efficacy and the Safety Analysis Set.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>CYD Dengue Vaccine Group</title>
          <description>Participants received 3 doses of CYD dengue vaccine; one each at 0, 6, and 12 months and were followed up to 60 months after last vaccination (or a total duration of up to 72 months).</description>
        </group>
        <group group_id="P2">
          <title>Placebo Group</title>
          <description>Participants received 3 doses of placebo matched to vaccine; one each at 0, 6, and 12 months and were followed up to 60 months after last vaccination (or a total duration of up to 72 months).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Vaccination Phase (Up to 25 Months)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6851"/>
                <participants group_id="P2" count="3424"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6797"/>
                <participants group_id="P2" count="3397"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Serious adverse event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Surveillance Expansion Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6797"/>
                <participants group_id="P2" count="3397"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6595"/>
                <participants group_id="P2" count="3279"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="202"/>
                <participants group_id="P2" count="118"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="180"/>
                <participants group_id="P2" count="105"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Serious adverse event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CYD Dengue Vaccine Group</title>
          <description>Participants received 3 doses of CYD dengue vaccine; one each at 0, 6, and 12 months and were followed up to 60 months after last vaccination (or a total duration of up to 72 months).</description>
        </group>
        <group group_id="B2">
          <title>Placebo Group</title>
          <description>Participants received 3 doses of placebo vaccine, one each at 0, 6, and 12 months and were followed up to 60 months after last vaccination (or a total duration of up to 72 months).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6851"/>
            <count group_id="B2" value="3424"/>
            <count group_id="B3" value="10275"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6851"/>
                    <measurement group_id="B2" value="3424"/>
                    <measurement group_id="B3" value="10275"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Age Continuous</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.8" spread="3.45"/>
                    <measurement group_id="B2" value="8.8" spread="3.42"/>
                    <measurement group_id="B3" value="8.8" spread="3.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3524"/>
                    <measurement group_id="B2" value="1767"/>
                    <measurement group_id="B3" value="5291"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3327"/>
                    <measurement group_id="B2" value="1657"/>
                    <measurement group_id="B3" value="4984"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Philippines</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2335"/>
                    <measurement group_id="B2" value="1166"/>
                    <measurement group_id="B3" value="3501"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaysia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="937"/>
                    <measurement group_id="B2" value="464"/>
                    <measurement group_id="B3" value="1401"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Indonesia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1246"/>
                    <measurement group_id="B2" value="624"/>
                    <measurement group_id="B3" value="1870"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thailand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="778"/>
                    <measurement group_id="B2" value="392"/>
                    <measurement group_id="B3" value="1170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vietnam</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1555"/>
                    <measurement group_id="B2" value="778"/>
                    <measurement group_id="B3" value="2333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Symptomatic Virologically Confirmed Dengue (VCD) Cases Due to Any Serotype During the Active Phase Post-dose 3 Following Injection (Inj.) With Either CYD Dengue Vaccine or a Placebo</title>
        <description>Symptomatic VCD cases were defined as occurrence of acute febrile illness (temperature &gt;=38°C on at least 2 consecutive days) and confirmation of dengue virus infection by dengue reverse transcriptase polymerase chain reaction and/or dengue NS protein 1 antigen enzyme-linked immunosorbent assay. Vaccine efficacy was defined as 1 minus the ratio of density incidence due to any serotype after at least 1 dose in the CYD Dengue Vaccine Group over the density incidence of the Placebo Vaccine Group.</description>
        <time_frame>28 days and up to 13 months post-dose 3</time_frame>
        <population>Number of symptomatic VCD cases were assessed in the Per-Protocol Analysis Set for Efficacy</population>
        <group_list>
          <group group_id="O1">
            <title>CYD Dengue Vaccine Group</title>
            <description>Participants were to receive 3 doses of CYD dengue vaccine; one each at 0, 6, and 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Participants were to receive 3 doses of placebo vaccine, one each at 0, 6, and 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Symptomatic Virologically Confirmed Dengue (VCD) Cases Due to Any Serotype During the Active Phase Post-dose 3 Following Injection (Inj.) With Either CYD Dengue Vaccine or a Placebo</title>
          <description>Symptomatic VCD cases were defined as occurrence of acute febrile illness (temperature &gt;=38°C on at least 2 consecutive days) and confirmation of dengue virus infection by dengue reverse transcriptase polymerase chain reaction and/or dengue NS protein 1 antigen enzyme-linked immunosorbent assay. Vaccine efficacy was defined as 1 minus the ratio of density incidence due to any serotype after at least 1 dose in the CYD Dengue Vaccine Group over the density incidence of the Placebo Vaccine Group.</description>
          <population>Number of symptomatic VCD cases were assessed in the Per-Protocol Analysis Set for Efficacy</population>
          <units>Cases</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6709"/>
                <count group_id="O2" value="3350"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117"/>
                    <measurement group_id="O2" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The statistical methodology was based on the use of the two-sided 95% confidence interval (CI) of the vaccine efficacy (expressed in %). The CI was calculated using the exact method conditional on the total number of cases in both groups (exact method by Breslow &amp; Day). The vaccine efficacy of the CYD dengue vaccine was considered significant if the lower bound of its 95% CI was greater than 25%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Vaccine efficacy</param_type>
            <param_value>56.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>43.8</ci_lower_limit>
            <ci_upper_limit>66.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers of Antibodies Against Each Serotype With the Parental Dengue Virus Strain Before and Following Injection With Either CYD Dengue Tetravalent Vaccine or a Placebo</title>
        <description>Geometric mean titers against each of the 4 serotypes of dengue virus strains were assessed using the plaque reduction neutralization test (PRNT) in a pre-defined subset of participants.</description>
        <time_frame>Pre-injection 1, 28 days post Injections 2 and 3, 13 months (Visit 07) and 60 months (Visit 12) post-injection 3</time_frame>
        <population>Antibody titers against each dengue virus serotype strain were assessed in Full Analysis Set for Immunogenicity(FASI),which included a subset of participants who received at least one dose of vaccine and had a blood sample drawn and result available after the dose. Here,‘number analyzed’=participants with available data for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>CYD Dengue Vaccine Group</title>
            <description>Subset of participants who received at least one dose of CYD Dengue vaccine.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Subset of participants who received at least one dose of the placebo vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers of Antibodies Against Each Serotype With the Parental Dengue Virus Strain Before and Following Injection With Either CYD Dengue Tetravalent Vaccine or a Placebo</title>
          <description>Geometric mean titers against each of the 4 serotypes of dengue virus strains were assessed using the plaque reduction neutralization test (PRNT) in a pre-defined subset of participants.</description>
          <population>Antibody titers against each dengue virus serotype strain were assessed in Full Analysis Set for Immunogenicity(FASI),which included a subset of participants who received at least one dose of vaccine and had a blood sample drawn and result available after the dose. Here,‘number analyzed’=participants with available data for each specified category.</population>
          <units>Titers (1/dilution)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1323"/>
                <count group_id="O2" value="660"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dengue virus Serotype 1; Pre-Inj. 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1309"/>
                    <count group_id="O2" value="655"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.3" lower_limit="33.8" upper_limit="43.5"/>
                    <measurement group_id="O2" value="42.1" lower_limit="35" upper_limit="50.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 1; Post Inj. 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1317"/>
                    <count group_id="O2" value="654"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="153" lower_limit="137" upper_limit="170"/>
                    <measurement group_id="O2" value="46.1" lower_limit="38.2" upper_limit="55.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 1; Post Inj. 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1316"/>
                    <count group_id="O2" value="657"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="166" lower_limit="150" upper_limit="183"/>
                    <measurement group_id="O2" value="46.6" lower_limit="38.7" upper_limit="56.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 1; Year 1 Post Inj. 3 (V 07)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1290"/>
                    <count group_id="O2" value="634"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105" lower_limit="92.8" upper_limit="119"/>
                    <measurement group_id="O2" value="57.2" lower_limit="46.9" upper_limit="69.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 1; Year 5 Post Inj. 3 (V 12)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1275"/>
                    <count group_id="O2" value="640"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.2" lower_limit="72.5" upper_limit="91.0"/>
                    <measurement group_id="O2" value="77.6" lower_limit="65.4" upper_limit="92.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 2; Pre-Inj. 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1313"/>
                    <count group_id="O2" value="654"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.3" lower_limit="48.7" upper_limit="62.9"/>
                    <measurement group_id="O2" value="62.1" lower_limit="51.7" upper_limit="74.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 2; Post Inj. 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1316"/>
                    <count group_id="O2" value="655"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="360" lower_limit="329" upper_limit="394"/>
                    <measurement group_id="O2" value="69.5" lower_limit="57.7" upper_limit="83.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 2; Post Inj. 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1314"/>
                    <count group_id="O2" value="657"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="355" lower_limit="327" upper_limit="386"/>
                    <measurement group_id="O2" value="68.5" lower_limit="57.1" upper_limit="82.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 2; Year 1 Post-Inj. 3 (V 07)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1298"/>
                    <count group_id="O2" value="640"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="194" lower_limit="175" upper_limit="214"/>
                    <measurement group_id="O2" value="78.1" lower_limit="64.8" upper_limit="94.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 2; Year 5 Post-Inj. 3 (V 12)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1275"/>
                    <count group_id="O2" value="640"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144" lower_limit="130" upper_limit="160"/>
                    <measurement group_id="O2" value="102" lower_limit="86.8" upper_limit="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 3; Pre-Inj. 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1307"/>
                    <count group_id="O2" value="650"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.1" lower_limit="35.6" upper_limit="45.1"/>
                    <measurement group_id="O2" value="40.7" lower_limit="34.5" upper_limit="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 3; Post Inj. 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1313"/>
                    <count group_id="O2" value="656"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="203" lower_limit="184" upper_limit="223"/>
                    <measurement group_id="O2" value="40.8" lower_limit="34.6" upper_limit="48.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 3; Post Inj. 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1314"/>
                    <count group_id="O2" value="657"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="207" lower_limit="189" upper_limit="226"/>
                    <measurement group_id="O2" value="42.5" lower_limit="36.2" upper_limit="49.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 3; Year 1 Post Inj. 3 (V 07)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1298"/>
                    <count group_id="O2" value="639"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="186" lower_limit="168" upper_limit="206"/>
                    <measurement group_id="O2" value="62.1" lower_limit="51.8" upper_limit="74.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 3; Year 5 Post Inj. 3 (V 12)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1275"/>
                    <count group_id="O2" value="640"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120" lower_limit="108" upper_limit="133"/>
                    <measurement group_id="O2" value="76.2" lower_limit="65.3" upper_limit="89.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 4; Pre Inj. 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1313"/>
                    <count group_id="O2" value="653"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.3" lower_limit="22.9" upper_limit="28"/>
                    <measurement group_id="O2" value="26.2" lower_limit="22.6" upper_limit="30.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 4; Post Inj. 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1318"/>
                    <count group_id="O2" value="655"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151" lower_limit="139" upper_limit="163"/>
                    <measurement group_id="O2" value="24.4" lower_limit="21.3" upper_limit="28.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 4; Post Inj. 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1315"/>
                    <count group_id="O2" value="657"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151" lower_limit="141" upper_limit="162"/>
                    <measurement group_id="O2" value="26.0" lower_limit="22.6" upper_limit="29.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 4; Year 1 Post Inj. 3 (V 07)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1293"/>
                    <count group_id="O2" value="621"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.5" lower_limit="78.5" upper_limit="93"/>
                    <measurement group_id="O2" value="26.0" lower_limit="22.4" upper_limit="30.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 4; Year 5 Post Inj. 3 (V 12)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1275"/>
                    <count group_id="O2" value="640"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.7" lower_limit="60.3" upper_limit="71.6"/>
                    <measurement group_id="O2" value="40.1" lower_limit="34.8" upper_limit="46.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Antibody Titers &gt;= 10 1/Dilution (1/Dil) Against Each Dengue Virus Serotype Strain Before and Following Inj. With CYD Dengue Vaccine or Placebo</title>
        <description>Percentage of participants with antibody titers &gt;= 10 (1/Dil) against each serotypes of the dengue virus strains were assessed using PRNT in a pre-defined subset of participants.</description>
        <time_frame>Pre-injection 1, 28 days post Injections 2 and 3, 13 months (V 07) and 60 months (V 12) post-injection 3</time_frame>
        <population>Antibody titers against each dengue virus serotype strain were assessed in FASI, which included a subset of participants who received at least one dose of vaccine and had a blood sample drawn and result available after the dose. Here, ‘number analyzed’ = participants with available data for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>CYD Dengue Vaccine Group</title>
            <description>Subset of participants who received at least one dose of CYD Dengue vaccine</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Subset of participants who received at least one dose of placebo vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Antibody Titers &gt;= 10 1/Dilution (1/Dil) Against Each Dengue Virus Serotype Strain Before and Following Inj. With CYD Dengue Vaccine or Placebo</title>
          <description>Percentage of participants with antibody titers &gt;= 10 (1/Dil) against each serotypes of the dengue virus strains were assessed using PRNT in a pre-defined subset of participants.</description>
          <population>Antibody titers against each dengue virus serotype strain were assessed in FASI, which included a subset of participants who received at least one dose of vaccine and had a blood sample drawn and result available after the dose. Here, ‘number analyzed’ = participants with available data for each specified category.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1323"/>
                <count group_id="O2" value="660"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dengue virus Serotype 1; Pre-Inj. 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1309"/>
                    <count group_id="O2" value="655"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.0"/>
                    <measurement group_id="O2" value="51.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 1; Post Inj. 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1317"/>
                    <count group_id="O2" value="654"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.9"/>
                    <measurement group_id="O2" value="54.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 1; Post-Inj. 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1316"/>
                    <count group_id="O2" value="657"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.0"/>
                    <measurement group_id="O2" value="55.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 1; Year 1 Post-Inj. 3 (V 07)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1290"/>
                    <count group_id="O2" value="634"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.8"/>
                    <measurement group_id="O2" value="55.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 1; Year 5 Post-Inj 3 (V 12)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1275"/>
                    <count group_id="O2" value="640"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.2"/>
                    <measurement group_id="O2" value="70.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 2; Pre-Inj. 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1313"/>
                    <count group_id="O2" value="654"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.0"/>
                    <measurement group_id="O2" value="59.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 2; Post-Inj. 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1316"/>
                    <count group_id="O2" value="655"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.3"/>
                    <measurement group_id="O2" value="62.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 2; Post-Inj. 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1314"/>
                    <count group_id="O2" value="657"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.7"/>
                    <measurement group_id="O2" value="61.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 2; Year 1 Post-Inj. 3 (V 07)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1298"/>
                    <count group_id="O2" value="640"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.0"/>
                    <measurement group_id="O2" value="65.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 2; Year 5 Post-inj 3 (V 12)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1275"/>
                    <count group_id="O2" value="640"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                    <measurement group_id="O2" value="75.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 3; Pre-Inj. 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1307"/>
                    <count group_id="O2" value="650"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.8"/>
                    <measurement group_id="O2" value="59.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 3; Post-Inj. 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1313"/>
                    <count group_id="O2" value="656"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.7"/>
                    <measurement group_id="O2" value="60.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 3; Post-Inj. 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1314"/>
                    <count group_id="O2" value="657"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.0"/>
                    <measurement group_id="O2" value="61.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 3; Year 1 Post-Inj. 3 (V 07)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1298"/>
                    <count group_id="O2" value="639"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.6"/>
                    <measurement group_id="O2" value="62.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 3; Year5 Post-Inj. 3 (V 12)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1275"/>
                    <count group_id="O2" value="640"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.4"/>
                    <measurement group_id="O2" value="75.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 4; Pre-Inj. 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1313"/>
                    <count group_id="O2" value="653"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.6"/>
                    <measurement group_id="O2" value="50.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 4; Post-Inj. 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1318"/>
                    <count group_id="O2" value="655"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.1"/>
                    <measurement group_id="O2" value="51.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 4; Post-Inj. 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1315"/>
                    <count group_id="O2" value="657"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.0"/>
                    <measurement group_id="O2" value="53.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 4; Year 1 Post-Inj 3 (V 07)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1293"/>
                    <count group_id="O2" value="621"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.4"/>
                    <measurement group_id="O2" value="50.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 4; Year 5 Post-Inj 3 (V 12)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1275"/>
                    <count group_id="O2" value="640"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.8"/>
                    <measurement group_id="O2" value="65.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Symptomatic VCD Cases Due to Any Serotype Occurring 28 Days Post-dose 1 Following Injection With Either CYD Dengue Vaccine or a Placebo</title>
        <description>Symptomatic VCD cases were defined as occurrence of acute febrile illness (temperature &gt;= 38°C on at least 2 consecutive days) and confirmation of dengue virus infection by dengue reverse transcriptase polymerase chain reaction and/or dengue NS1 enzyme-linked immunosorbent assay. Vaccine efficacy was defined as 1 minus the ratio of density incidence due to any serotype after at least 1 dose in the CYD Dengue Vaccine Group over the density incidence of the Placebo Vaccine Group.</description>
        <time_frame>28 days post-injection 1 and up to 13 months post-injection 3</time_frame>
        <population>Number of symptomatic VCD cases were assessed in the Full Analysis Set for Efficacy, which included participants who received at least 1 dose of study vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>CYD Dengue Vaccine Group</title>
            <description>Participants were to receive 3 doses of CYD dengue vaccine; one each at 0, 6, and 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Participants were to receive 3 doses of placebo vaccine, one each at 0, 6, and 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Symptomatic VCD Cases Due to Any Serotype Occurring 28 Days Post-dose 1 Following Injection With Either CYD Dengue Vaccine or a Placebo</title>
          <description>Symptomatic VCD cases were defined as occurrence of acute febrile illness (temperature &gt;= 38°C on at least 2 consecutive days) and confirmation of dengue virus infection by dengue reverse transcriptase polymerase chain reaction and/or dengue NS1 enzyme-linked immunosorbent assay. Vaccine efficacy was defined as 1 minus the ratio of density incidence due to any serotype after at least 1 dose in the CYD Dengue Vaccine Group over the density incidence of the Placebo Vaccine Group.</description>
          <population>Number of symptomatic VCD cases were assessed in the Full Analysis Set for Efficacy, which included participants who received at least 1 dose of study vaccine.</population>
          <units>Cases</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6848"/>
                <count group_id="O2" value="3424"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="276"/>
                    <measurement group_id="O2" value="302"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The statistical methodology was based on the use of the two-sided 95% CI of the vaccine efficacy (expressed in %) calculated using the exact method conditional on the total number of cases in both groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Vaccine Efficacy</param_type>
            <param_value>55.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>47.3</ci_lower_limit>
            <ci_upper_limit>62.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Symptomatic VCD Cases Due to Any Serotype 28 Days Post-dose 2 Following Injection With Either CYD Dengue Vaccine or a Placebo</title>
        <description>Symptomatic VCD cases were defined as occurrence of acute febrile illness (temperature &gt;= 38°C on at least 2 consecutive days) and confirmation of dengue virus infection by dengue reverse transcriptase polymerase chain reaction and/or dengue NS1 enzyme-linked immunosorbent assay. Vaccine efficacy was defined as 1 minus the ratio of density incidence due to any serotype after at least 1 dose in the CYD Dengue Vaccine Group over the density incidence of the Placebo Vaccine Group.</description>
        <time_frame>28 days post-injection 2 and up to 13 months post-injection 3</time_frame>
        <population>Number of symptomatic VCD cases were assessed in the Other Efficacy Analysis Set, which included participants who received at least 2 doses of study vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>CYD Dengue Vaccine Group</title>
            <description>Participants were to receive 3 doses of CYD dengue vaccine; one each at 0, 6, and 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Participants were to receive 3 doses of placebo vaccine, one each at 0, 6, and 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Symptomatic VCD Cases Due to Any Serotype 28 Days Post-dose 2 Following Injection With Either CYD Dengue Vaccine or a Placebo</title>
          <description>Symptomatic VCD cases were defined as occurrence of acute febrile illness (temperature &gt;= 38°C on at least 2 consecutive days) and confirmation of dengue virus infection by dengue reverse transcriptase polymerase chain reaction and/or dengue NS1 enzyme-linked immunosorbent assay. Vaccine efficacy was defined as 1 minus the ratio of density incidence due to any serotype after at least 1 dose in the CYD Dengue Vaccine Group over the density incidence of the Placebo Vaccine Group.</description>
          <population>Number of symptomatic VCD cases were assessed in the Other Efficacy Analysis Set, which included participants who received at least 2 doses of study vaccine.</population>
          <units>Cases</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6793"/>
                <count group_id="O2" value="3397"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="205"/>
                    <measurement group_id="O2" value="238"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The statistical methodology was based on the use of the two-sided 95% CI of the vaccine efficacy (expressed in %) calculated using the exact method conditional on the total number of cases in both groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Vaccine Efficacy</param_type>
            <param_value>57.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>49.0</ci_lower_limit>
            <ci_upper_limit>65.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Symptomatic VCD Cases Due to Any Serotype During the Active Phase in Either CYD Dengue Vaccine or Placebo Group</title>
        <description>Symptomatic VCD cases were defined as occurrence of acute febrile illness (temperature &gt;=38°C on at least 2 consecutive days) and confirmation of dengue virus infection by dengue reverse transcriptase polymerase chain reaction and/or dengue NS1 enzyme-linked immunosorbent assay. Vaccine efficacy was defined as 1 minus the ratio of density incidence due to any serotype after at least 1 dose in the CYD Dengue Vaccine Group over the density incidence of the Placebo Vaccine Group.</description>
        <time_frame>Day 0 up to 13 months post-injection 3</time_frame>
        <population>Number of symptomatic VCD cases were assessed in the Full Analysis Set for Efficacy, which included all participants who received at least 1 injection.</population>
        <group_list>
          <group group_id="O1">
            <title>CYD Dengue Vaccine Group</title>
            <description>Participants were to receive 3 doses of CYD dengue vaccine; one each at 0, 6, and 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Participants were to receive 3 doses of placebo vaccine, one each at 0, 6, and 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Symptomatic VCD Cases Due to Any Serotype During the Active Phase in Either CYD Dengue Vaccine or Placebo Group</title>
          <description>Symptomatic VCD cases were defined as occurrence of acute febrile illness (temperature &gt;=38°C on at least 2 consecutive days) and confirmation of dengue virus infection by dengue reverse transcriptase polymerase chain reaction and/or dengue NS1 enzyme-linked immunosorbent assay. Vaccine efficacy was defined as 1 minus the ratio of density incidence due to any serotype after at least 1 dose in the CYD Dengue Vaccine Group over the density incidence of the Placebo Vaccine Group.</description>
          <population>Number of symptomatic VCD cases were assessed in the Full Analysis Set for Efficacy, which included all participants who received at least 1 injection.</population>
          <units>Cases</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6848"/>
                <count group_id="O2" value="3424"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="286"/>
                    <measurement group_id="O2" value="309"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The statistical methodology was based on the use of the two-sided 95% CI of the vaccine efficacy (expressed in %) calculated using the exact method conditional on the total number of cases in both groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Vaccine Efficacy</param_type>
            <param_value>54.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>46.8</ci_lower_limit>
            <ci_upper_limit>61.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Symptomatic VCD Cases Meeting 1997 WHO Criteria Throughout the Trial Due to Any Serotype Following Injection With Either CYD Dengue Vaccine or a Placebo</title>
        <description>Dengue hemorrhagic fever cases were defined as number of participants with at least one symptomatic VCD episode meeting the 1997 WHO criteria.
(a) Fever: acute onset, high (&gt;= 38°C) and continuous, lasting 2 to 7 days and (b) any of the pre-listed hemorrhagic manifestations and laboratory findings of thrombocytopenia (platelet &lt;=100 x 109/L) and plasma leakage as shown by hemoconcentation (hematocrit increased by 20% or more) or pleural effusion (seen on CXR) and/or ascites and/or hypoaluminemia. The first two clinical criteria plus thrombocytopenia and signs of plasma leakage are enough to establish a clinical diagnosis of DHF. Dengue hemorrhagic fever was graded as follows: Grade I: Fever accompanied by non-specific constitutional symptoms; the only hemorrhagic manifestation is a positive tourniquet test; Grade II: Spontaneous bleeding in addition to the manifestations of Grade I participants, usually in the form of skin and/or other hemorrhage.</description>
        <time_frame>Day 0 to the end of study (up to 72 months)</time_frame>
        <population>Number of WHO dengue hemorrhagic fever cases were assessed in the Safety Analysis Set, which included all participants who received at least one dose of study vaccine. Here, ‘number analyzed’ = participants with available data for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>CYD Dengue Vaccine Group</title>
            <description>Participants were to receive 3 doses of CYD dengue vaccine; one each at 0, 6, and 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Participants were to receive 3 doses of placebo vaccine, one each at 0, 6, and 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Symptomatic VCD Cases Meeting 1997 WHO Criteria Throughout the Trial Due to Any Serotype Following Injection With Either CYD Dengue Vaccine or a Placebo</title>
          <description>Dengue hemorrhagic fever cases were defined as number of participants with at least one symptomatic VCD episode meeting the 1997 WHO criteria.
(a) Fever: acute onset, high (&gt;= 38°C) and continuous, lasting 2 to 7 days and (b) any of the pre-listed hemorrhagic manifestations and laboratory findings of thrombocytopenia (platelet &lt;=100 x 109/L) and plasma leakage as shown by hemoconcentation (hematocrit increased by 20% or more) or pleural effusion (seen on CXR) and/or ascites and/or hypoaluminemia. The first two clinical criteria plus thrombocytopenia and signs of plasma leakage are enough to establish a clinical diagnosis of DHF. Dengue hemorrhagic fever was graded as follows: Grade I: Fever accompanied by non-specific constitutional symptoms; the only hemorrhagic manifestation is a positive tourniquet test; Grade II: Spontaneous bleeding in addition to the manifestations of Grade I participants, usually in the form of skin and/or other hemorrhage.</description>
          <population>Number of WHO dengue hemorrhagic fever cases were assessed in the Safety Analysis Set, which included all participants who received at least one dose of study vaccine. Here, ‘number analyzed’ = participants with available data for each specified category.</population>
          <units>Cases</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6848"/>
                <count group_id="O2" value="3424"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Due to Any of the 4 Serotypes: Any Grade</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6745"/>
                    <count group_id="O2" value="3369"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Due to Any of the 4 Serotypes: Grade I</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6745"/>
                    <count group_id="O2" value="3369"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Due to Any of the 4 Serotypes: Grade II</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6745"/>
                    <count group_id="O2" value="3369"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Due to Any of the 4 Serotypes: Grade III</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6745"/>
                    <count group_id="O2" value="3369"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Due to Any of the 4 Serotypes: Grade IV</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6745"/>
                    <count group_id="O2" value="3369"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Symptomatic VCD Cases Meeting 1997 WHO Criteria During the Surveillance Expansion Period Due to Any Serotype Following Inj. With Either CYD Dengue Vaccine or a Placebo</title>
        <description>The 1997 WHO criteria are: a) Fever: acute onset, high (&gt;= 38°C) and continuous, for 2 to 7 days and (b) any of the following: thrombocytopenia (platelet &lt;=100 x 109/L) and plasma leakage as shown by hematocrit increased by 20% or more or pleural effusion and/or ascites and/or hypoaluminemia. The first two clinical criteria plus thrombocytopenia and signs of plasma leakage are enough to establish diagnosis of DHF. Dengue hemorrhagic fever was graded as follows:Grade I: Fever accompanied by non-specific constitutional symptoms; the only hemorrhagic manifestation is a positive tourniquet test; Grade II: Spontaneous bleeding in addition to the manifestations of Grade I participant,usually in the form of skin and/or other hemorrhages; Grade III: Circulatory failure manifested by rapid and weak pulse, narrowing of pulse pressure (20 mmHg or less) or hypotension, with the presence of cold clammy skin and restlessness; and Grade IV: Profound shock with undetectable blood pressure and pulse.</description>
        <time_frame>From consent to participate int the Surveillance Expansion Period to 60 months post-injection 3 (up to Month 72)</time_frame>
        <population>Number of WHO dengue hemorrhagic fever cases were assessed in the Full Analysis Set for Surveillance Expansion Period, which included all participants who received at least 1 injection and accepted to be included in the Surveillance Expansion Period.</population>
        <group_list>
          <group group_id="O1">
            <title>CYD Dengue Vaccine Group</title>
            <description>Participants were to receive 3 doses of CYD dengue vaccine; one each at 0, 6, and 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Participant were to receive 3 doses of placebo vaccine, one each at 0, 6, and 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Symptomatic VCD Cases Meeting 1997 WHO Criteria During the Surveillance Expansion Period Due to Any Serotype Following Inj. With Either CYD Dengue Vaccine or a Placebo</title>
          <description>The 1997 WHO criteria are: a) Fever: acute onset, high (&gt;= 38°C) and continuous, for 2 to 7 days and (b) any of the following: thrombocytopenia (platelet &lt;=100 x 109/L) and plasma leakage as shown by hematocrit increased by 20% or more or pleural effusion and/or ascites and/or hypoaluminemia. The first two clinical criteria plus thrombocytopenia and signs of plasma leakage are enough to establish diagnosis of DHF. Dengue hemorrhagic fever was graded as follows:Grade I: Fever accompanied by non-specific constitutional symptoms; the only hemorrhagic manifestation is a positive tourniquet test; Grade II: Spontaneous bleeding in addition to the manifestations of Grade I participant,usually in the form of skin and/or other hemorrhages; Grade III: Circulatory failure manifested by rapid and weak pulse, narrowing of pulse pressure (20 mmHg or less) or hypotension, with the presence of cold clammy skin and restlessness; and Grade IV: Profound shock with undetectable blood pressure and pulse.</description>
          <population>Number of WHO dengue hemorrhagic fever cases were assessed in the Full Analysis Set for Surveillance Expansion Period, which included all participants who received at least 1 injection and accepted to be included in the Surveillance Expansion Period.</population>
          <units>Cases</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6327"/>
                <count group_id="O2" value="3138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Due to Any of the 4 Serotypes: Any Grade</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Due to Any of the 4 Serotypes: Grade I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Due to Any of the 4 Serotypes: Grade II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Due to Any of the 4 Serotypes: Grade III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Due to Any of the 4 Serotypes: Grade IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Clinically Severe VCD Cases Throughout the Trial Due to Any Serotype Following Inj. With Either CYD Dengue Vaccine or a Placebo</title>
        <description>The severity of VCD cases was assessed by an IDMC based on a medical review of cases and any of the following criteria:1) Platelet count &lt;=100000 μl and bleeding (tourniquet, petechiae or any bleeding) plus plasma leakage 2) Shock (pulse pressure &lt;= 20 mmHg in a child, or hypotension [&lt;= 90 mmHg] with tachycardia, weak pulse and poor perfusion) 3) Bleeding requiring blood transfusion 4) Encephalopathy i.e. Unconsciousness or poor conscious state or fitting not attributable to simple febrile convulsion or focal neurological signs. Poor conscious state or unconsciousness must be supported by GCS score 5) Liver impairment (AST &gt;1000 IU/L or PT INR &gt;1.5) excluding other causes of viral hepatitis 6) Impaired kidney function (serum creatinine &gt;= 1.5 mg/dL) 7) Myocarditis, pericarditis or clinical heart failure supported by CXR, echocardiography, ECG or cardiac enzymes.</description>
        <time_frame>Day 0 to the end of study (up to 72 months)</time_frame>
        <population>Number of clinically severe VCD cases were assessed in the Safety Analysis Set. Here, ‘number analyzed’ = participants with available data for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>CYD Dengue Vaccine Group</title>
            <description>Participants were to receive 3 doses of CYD dengue vaccine; one each at 0, 6, and 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Participant were to receive 3 doses of placebo vaccine, one each at 0, 6, and 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Clinically Severe VCD Cases Throughout the Trial Due to Any Serotype Following Inj. With Either CYD Dengue Vaccine or a Placebo</title>
          <description>The severity of VCD cases was assessed by an IDMC based on a medical review of cases and any of the following criteria:1) Platelet count &lt;=100000 μl and bleeding (tourniquet, petechiae or any bleeding) plus plasma leakage 2) Shock (pulse pressure &lt;= 20 mmHg in a child, or hypotension [&lt;= 90 mmHg] with tachycardia, weak pulse and poor perfusion) 3) Bleeding requiring blood transfusion 4) Encephalopathy i.e. Unconsciousness or poor conscious state or fitting not attributable to simple febrile convulsion or focal neurological signs. Poor conscious state or unconsciousness must be supported by GCS score 5) Liver impairment (AST &gt;1000 IU/L or PT INR &gt;1.5) excluding other causes of viral hepatitis 6) Impaired kidney function (serum creatinine &gt;= 1.5 mg/dL) 7) Myocarditis, pericarditis or clinical heart failure supported by CXR, echocardiography, ECG or cardiac enzymes.</description>
          <population>Number of clinically severe VCD cases were assessed in the Safety Analysis Set. Here, ‘number analyzed’ = participants with available data for each specified category.</population>
          <units>Cases</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6745"/>
                <count group_id="O2" value="3369"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Clinically Severe VCD Cases During the Surveillance Expansion Period Due to Any Serotype Following Inj. With Either CYD Dengue Vaccine or a Placebo</title>
        <description>The severity of VCD cases was assessed by an IDMC based on a medical review of cases and any of the following criteria:1) Platelet count &lt;=100000μl and bleeding (tourniquet, petechiae or any bleeding) plus plasma leakage 2) Shock (pulse pressure &lt;= 20mmHg in a child, or hypotension [&lt;= 90 mmHg] with tachycardia, weak pulse and poor perfusion) 3) Bleeding requiring blood transfusion 4) Encephalopathy i.e. Unconsciousness or poor conscious state or fitting not attributable to simple febrile convulsion or focal neurological signs. Poor conscious state or unconsciousness must be supported by GCS score 5) Liver impairment (AST &gt;1000 IU/L or PT INR &gt;1.5) excluding other causes of viral hepatitis 6) Impaired kidney function (serum creatinine &gt;= 1.5 mg/dL) 7) Myocarditis, pericarditis or clinical heart failure supported by CXR, echocardiography, ECG or cardiac enzymes.</description>
        <time_frame>From consent to participate in the Surveillance Expansion Period to 60 months post-injection 3 (up to Month 72)</time_frame>
        <population>Number of clinically severe VCD cases were assessed in the Full Analysis Set for SEP.</population>
        <group_list>
          <group group_id="O1">
            <title>CYD Dengue Vaccine Group</title>
            <description>Participants were to receive 3 doses of CYD dengue vaccine; one each at 0, 6, and 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Participant were to receive 3 doses of placebo vaccine, one each at 0, 6, and 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Clinically Severe VCD Cases During the Surveillance Expansion Period Due to Any Serotype Following Inj. With Either CYD Dengue Vaccine or a Placebo</title>
          <description>The severity of VCD cases was assessed by an IDMC based on a medical review of cases and any of the following criteria:1) Platelet count &lt;=100000μl and bleeding (tourniquet, petechiae or any bleeding) plus plasma leakage 2) Shock (pulse pressure &lt;= 20mmHg in a child, or hypotension [&lt;= 90 mmHg] with tachycardia, weak pulse and poor perfusion) 3) Bleeding requiring blood transfusion 4) Encephalopathy i.e. Unconsciousness or poor conscious state or fitting not attributable to simple febrile convulsion or focal neurological signs. Poor conscious state or unconsciousness must be supported by GCS score 5) Liver impairment (AST &gt;1000 IU/L or PT INR &gt;1.5) excluding other causes of viral hepatitis 6) Impaired kidney function (serum creatinine &gt;= 1.5 mg/dL) 7) Myocarditis, pericarditis or clinical heart failure supported by CXR, echocardiography, ECG or cardiac enzymes.</description>
          <population>Number of clinically severe VCD cases were assessed in the Full Analysis Set for SEP.</population>
          <units>Cases</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6327"/>
                <count group_id="O2" value="3138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Solicited Injection Site Reactions Following Any and Each Inj. With Either CYD Dengue Vaccine or a Placebo</title>
        <description>Solicited injection site reactions: Pain, Erythema, and Swelling. Grade 3 reactions (2-11 years): Pain, Incapacitating, unable to perform usual activities; Erythema and Swelling, &gt;= 50 mm. Grade 3 Solicited injection site reactions (12-14 years): Pain, Significant, prevents daily activity; Erythema and Swelling, &gt;100 mm.</description>
        <time_frame>Within 7 days after injection</time_frame>
        <population>Solicited injection site reactions were assessed in a subset of the Safety Analysis Set, which included all participants who received at least one dose of study vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>CYD Dengue Vaccine Group</title>
            <description>Participants were to receive 3 doses of CYD dengue vaccine; one each at 0, 6, and 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Participants were to receive 3 doses of placebo vaccine, one each at 0, 6, and 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Solicited Injection Site Reactions Following Any and Each Inj. With Either CYD Dengue Vaccine or a Placebo</title>
          <description>Solicited injection site reactions: Pain, Erythema, and Swelling. Grade 3 reactions (2-11 years): Pain, Incapacitating, unable to perform usual activities; Erythema and Swelling, &gt;= 50 mm. Grade 3 Solicited injection site reactions (12-14 years): Pain, Significant, prevents daily activity; Erythema and Swelling, &gt;100 mm.</description>
          <population>Solicited injection site reactions were assessed in a subset of the Safety Analysis Set, which included all participants who received at least one dose of study vaccine.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1334"/>
                <count group_id="O2" value="663"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Injection-site Pain (Post any injection)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1332"/>
                    <count group_id="O2" value="663"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="614"/>
                    <measurement group_id="O2" value="275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection-site Erythema (Post-any injection)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1332"/>
                    <count group_id="O2" value="663"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107"/>
                    <measurement group_id="O2" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection-site Swelling (Post any injection)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1332"/>
                    <count group_id="O2" value="663"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection-site Pain (Post-injection 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1332"/>
                    <count group_id="O2" value="663"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="406"/>
                    <measurement group_id="O2" value="196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection-site Pain (Post-injection 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1332"/>
                    <count group_id="O2" value="663"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection-site Erythema (Post-injection 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1332"/>
                    <count group_id="O2" value="663"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection-site Erythema (Post-injection 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1332"/>
                    <count group_id="O2" value="663"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection-site Swelling (Post-injection 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1332"/>
                    <count group_id="O2" value="663"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection-site Swelling (Post-injection 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1332"/>
                    <count group_id="O2" value="663"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection-site Pain (Post-injection 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1319"/>
                    <count group_id="O2" value="658"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="303"/>
                    <measurement group_id="O2" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection-site Pain (Post-injection 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1319"/>
                    <count group_id="O2" value="658"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection-site Erythema (Post-injection 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1319"/>
                    <count group_id="O2" value="658"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection-site Erythema (Post-injection 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1319"/>
                    <count group_id="O2" value="658"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection-site Swelling (Post-injection 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1319"/>
                    <count group_id="O2" value="658"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection-site Swelling (Post-injection 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1319"/>
                    <count group_id="O2" value="658"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection-site Pain (Post-injection 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1313"/>
                    <count group_id="O2" value="654"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="283"/>
                    <measurement group_id="O2" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection-site Pain (Post-injection 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1313"/>
                    <count group_id="O2" value="654"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection-site Erythema (Post-injection 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1313"/>
                    <count group_id="O2" value="654"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection-site Erythema (Post-injection 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1313"/>
                    <count group_id="O2" value="654"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection-site Swelling (Post-injection 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1313"/>
                    <count group_id="O2" value="654"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection-site Swelling (Post-injection 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1313"/>
                    <count group_id="O2" value="654"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Systemic Reactions Following Any and Each Inj. With Either CYD Dengue Vaccine or a Placebo</title>
        <description>Solicited systemic reactions: Fever (Temperature), Headache, Malaise, Myalgia, and Asthenia. Grade 3 reactions: Fever, &gt;= 39°C; Headache, Malaise, Myalgia, and Asthenia, Significant, prevents daily activity.</description>
        <time_frame>Within 14 days after injection</time_frame>
        <population>Solicited systemic reactions were assessed in a subset of the Safety Analysis Set, which included all participants who received at least one dose of study vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>CYD Dengue Vaccine Group</title>
            <description>Participants were to receive 3 doses of CYD dengue vaccine; one each at 0, 6, and 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Participants were to receive 3 doses of placebo vaccine, one each at 0, 6, and 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Systemic Reactions Following Any and Each Inj. With Either CYD Dengue Vaccine or a Placebo</title>
          <description>Solicited systemic reactions: Fever (Temperature), Headache, Malaise, Myalgia, and Asthenia. Grade 3 reactions: Fever, &gt;= 39°C; Headache, Malaise, Myalgia, and Asthenia, Significant, prevents daily activity.</description>
          <population>Solicited systemic reactions were assessed in a subset of the Safety Analysis Set, which included all participants who received at least one dose of study vaccine.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1334"/>
                <count group_id="O2" value="663"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever (Post any injection)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1332"/>
                    <count group_id="O2" value="663"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="248"/>
                    <measurement group_id="O2" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (Post any injection)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1332"/>
                    <count group_id="O2" value="663"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="562"/>
                    <measurement group_id="O2" value="259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise (Post any injection)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1332"/>
                    <count group_id="O2" value="663"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="476"/>
                    <measurement group_id="O2" value="239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia (Post any injection)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1332"/>
                    <count group_id="O2" value="663"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="414"/>
                    <measurement group_id="O2" value="197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asthenia (Post any injection)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1332"/>
                    <count group_id="O2" value="663"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="378"/>
                    <measurement group_id="O2" value="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (Post-injection 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1330"/>
                    <count group_id="O2" value="663"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever (Post-injection 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1330"/>
                    <count group_id="O2" value="663"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (Post-injection 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1332"/>
                    <count group_id="O2" value="663"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="387"/>
                    <measurement group_id="O2" value="168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Headache (Post-injection 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1332"/>
                    <count group_id="O2" value="663"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise (Post-injection 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1332"/>
                    <count group_id="O2" value="663"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="312"/>
                    <measurement group_id="O2" value="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Malaise (Post-injection 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1332"/>
                    <count group_id="O2" value="663"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia (Post-injection 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1332"/>
                    <count group_id="O2" value="663"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="255"/>
                    <measurement group_id="O2" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Myalgia (Post-injection 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1332"/>
                    <count group_id="O2" value="663"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asthenia (Post-injection 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1332"/>
                    <count group_id="O2" value="663"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="229"/>
                    <measurement group_id="O2" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Asthenia (Post-injection 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1332"/>
                    <count group_id="O2" value="663"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (Post-injection 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1320"/>
                    <count group_id="O2" value="657"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever (Post-injection 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1320"/>
                    <count group_id="O2" value="657"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (Post-injection 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1319"/>
                    <count group_id="O2" value="658"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="247"/>
                    <measurement group_id="O2" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Headache (Post-injection 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1319"/>
                    <count group_id="O2" value="658"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise (Post-injection 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1319"/>
                    <count group_id="O2" value="658"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="192"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Malaise (Post-injection 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1319"/>
                    <count group_id="O2" value="658"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia (Post-injection 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1319"/>
                    <count group_id="O2" value="658"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="174"/>
                    <measurement group_id="O2" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Myalgia (Post-injection 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1319"/>
                    <count group_id="O2" value="658"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asthenia (Post-injection 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1319"/>
                    <count group_id="O2" value="658"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158"/>
                    <measurement group_id="O2" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Asthenia (Post-injection 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1319"/>
                    <count group_id="O2" value="658"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (Post-injection 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1309"/>
                    <count group_id="O2" value="654"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever (Post-injection 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1309"/>
                    <count group_id="O2" value="654"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (Post-injection 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1313"/>
                    <count group_id="O2" value="654"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="219"/>
                    <measurement group_id="O2" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Headache (Post-injection 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1313"/>
                    <count group_id="O2" value="654"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise (Post-injection 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1313"/>
                    <count group_id="O2" value="654"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="183"/>
                    <measurement group_id="O2" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Malaise (Post-injection 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1313"/>
                    <count group_id="O2" value="654"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia (Post-injection 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1313"/>
                    <count group_id="O2" value="654"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156"/>
                    <measurement group_id="O2" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Myalgia (Post-injection 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1313"/>
                    <count group_id="O2" value="654"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asthenia (Post-injection 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1313"/>
                    <count group_id="O2" value="654"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142"/>
                    <measurement group_id="O2" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Asthenia (Post-injection 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1313"/>
                    <count group_id="O2" value="654"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Hospitalized VCD Cases Throughout the Trial Due to Any Serotype Following Injection With Either CYD Dengue Vaccine or a Placebo</title>
        <description>Hospitalized VCD cases were defined as VCD confirmed by dengue RT-PCR and/or dengue NS1 ELISA in participants with acute febrile illness (temperature &gt;=38°C on at least 2 consecutive days) requiring hospitalization.</description>
        <time_frame>Day 0 to the end of study (up to 72 months)</time_frame>
        <population>Number of hospitalized dengue hemorrhagic fever cases were assessed in the Safety Analysis Set. Here, ‘number analyzed’ = participants with available data for specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>CYD Dengue Vaccine Group</title>
            <description>Participants were to receive 3 doses of CYD dengue vaccine; one each at 0, 6, and 12 months and were followed up to 60 months after last vaccination (up to 72 months).</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Participants were to receive 3 doses of placebo matched to vaccine; one each at 0, 6, and 12 months and were followed up to 60 months after last vaccination (up to 72 months).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Hospitalized VCD Cases Throughout the Trial Due to Any Serotype Following Injection With Either CYD Dengue Vaccine or a Placebo</title>
          <description>Hospitalized VCD cases were defined as VCD confirmed by dengue RT-PCR and/or dengue NS1 ELISA in participants with acute febrile illness (temperature &gt;=38°C on at least 2 consecutive days) requiring hospitalization.</description>
          <population>Number of hospitalized dengue hemorrhagic fever cases were assessed in the Safety Analysis Set. Here, ‘number analyzed’ = participants with available data for specified category.</population>
          <units>Cases</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6745"/>
                <count group_id="O2" value="3369"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="210"/>
                    <measurement group_id="O2" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Hospitalized VCD Cases During the Surveillance Expansion Period Due to Any Serotype Following Injection With Either CYD Dengue Vaccine or a Placebo</title>
        <description>Hospitalized VCD cases were defined as VCD confirmed by dengue RT-PCR and/or dengue NS1 ELISA in participants with acute febrile illness (temperature &gt;= 38°C on at least 2 consecutive days) requiring hospitalization.</description>
        <time_frame>From consent to participate in the Surveillance Expansion Period to 60 months post-injection 3 (up to Month 72)</time_frame>
        <population>Number of hospitalized dengue hemorrhagic fever cases were assessed in the Safety Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>CYD Dengue Vaccine Group</title>
            <description>Participants were to receive 3 doses of CYD dengue vaccine; one each at 0, 6, and 12 months and were followed up to 60 months after last vaccination (up to 72 months).</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Participants were to receive 3 doses of placebo matched to vaccine; one each at 0, 6, and 12 months and were followed up to 60 months after last vaccination (up to 72 months).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Hospitalized VCD Cases During the Surveillance Expansion Period Due to Any Serotype Following Injection With Either CYD Dengue Vaccine or a Placebo</title>
          <description>Hospitalized VCD cases were defined as VCD confirmed by dengue RT-PCR and/or dengue NS1 ELISA in participants with acute febrile illness (temperature &gt;= 38°C on at least 2 consecutive days) requiring hospitalization.</description>
          <population>Number of hospitalized dengue hemorrhagic fever cases were assessed in the Safety Analysis Set.</population>
          <units>Cases</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6848"/>
                <count group_id="O2" value="3424"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected from Day 0 (post-vaccination) up to 60 months post-injection 3 (up to 72 months).</time_frame>
      <desc>All the vaccinated participants were assessed for SAE during the trial. Non-serious adverse events included solicited injection-site (within 7 days after injection) and solicited systemic reactions (within 14 days after injection), as well as unsolicited non-serious adverse events (within 28 days after injection). These events were assessed in a subset of participants from each group, who had received at least 1 dose of study vaccine.</desc>
      <group_list>
        <group group_id="E1">
          <title>CYD Dengue Vaccine Group</title>
          <description>Participants were to receive 3 doses of CYD dengue vaccine; one each at 0, 6, and 12 months.</description>
        </group>
        <group group_id="E2">
          <title>Placebo Group</title>
          <description>Participants were to receive 3 doses of placebo vaccine; one each at 0, 6, and 12 months.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDra 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="6848"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="947" subjects_at_risk="6848"/>
                <counts group_id="E2" subjects_affected="552" subjects_at_risk="3424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Anaemia Of Pregnancy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Haemorrhagic Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Iron Deficiency Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Cardiogenic Shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Rheumatic Heart Disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Supraventricular Tachycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Ventricular Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Cryptorchism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Duchenne Muscular Dystrophy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Familial Periodic Paralysis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Fibrous Dysplasia Of Bone</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Odontogenic Cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Phimosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Middle Ear Effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Vertigo Positional</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Vestibular Disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Chalazion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Choroidal Dystrophy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Corneal Oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Lower</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Anal Fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Caecitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Dental Caries</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6848"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="6848"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6848"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Food Poisoning</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="6848"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="32" subjects_affected="31" subjects_at_risk="6848"/>
                <counts group_id="E2" events="16" subjects_affected="14" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Disorder</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="6848"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal Reflux Disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Inguinal Hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Mouth Cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Pancreatitis Acute</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Pancreatitis Chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Salivary Gland Calculus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Salivary Gland Mucocoele</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Tooth Development Disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Tooth Impacted</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Drowning</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Hernia Obstructive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy To Arthropod Bite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Allergy To Arthropod Sting</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Anaphylactic Reaction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Anaphylactic Shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Drug Hypersensitivity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Food Allergy</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6848"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess Limb</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Abscess Neck</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Abscess Of External Auditory Meatus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Acinetobacter Bacteraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Acute Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Acute Tonsillitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="6848"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Adenoiditis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Amoebiasis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="6848"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Amoebic Dysentery</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6848"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Anal Abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Appendiceal Abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="33" subjects_affected="33" subjects_at_risk="6848"/>
                <counts group_id="E2" events="27" subjects_affected="27" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Appendicitis Perforated</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6848"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Bacterial Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Bacterial Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Bartholin's Abscess</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="6848"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Bronchitis Bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Brucellosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="6848"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Chikungunya Virus Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Chronic Tonsillitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Conjunctivitis Infective</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Dengue Fever</sub_title>
                <counts group_id="E1" events="241" subjects_affected="238" subjects_at_risk="6848"/>
                <counts group_id="E2" events="167" subjects_affected="158" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Diarrhoea Infectious</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6848"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Disseminated Tuberculosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Encephalitis Viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Endophthalmitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Gastritis Bacterial</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="64" subjects_affected="53" subjects_at_risk="6848"/>
                <counts group_id="E2" events="43" subjects_affected="40" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Gastroenteritis Bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Gastroenteritis Viral</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Bacterial Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6848"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Groin Abscess</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Hiv Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Hand-Foot-And-Mouth Disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Hepatitis A</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Hepatitis Viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Herpangina</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Herpes Zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Infection In An Immunocompromised Host</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="6848"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Leptospirosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Lobar Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Lymphadenitis Bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Measles</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Meningitis Aseptic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Meningitis Bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Mumps</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Oral Herpes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Otitis Externa</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Otitis Media</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Otitis Media Chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Paratyphoid Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Parotitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Periorbital Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Peritonsillar Abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="35" subjects_affected="32" subjects_at_risk="6848"/>
                <counts group_id="E2" events="25" subjects_affected="19" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Pharyngitis Bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Pharyngitis Streptococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="6848"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Plasmodium Falciparum Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="37" subjects_affected="33" subjects_at_risk="6848"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Pneumonia Bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Pneumonia Measles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Pneumonia Primary Atypical</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6848"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Pneumonia Viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Postoperative Wound Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Pulmonary Tuberculosis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6848"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Pyelonephritis Acute</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6848"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Scarlet Fever</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6848"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6848"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Staphylococcal Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Streptococcal Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="6848"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Tonsillitis Bacterial</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Tooth Abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Tuberculous Pleurisy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Typhoid Fever</sub_title>
                <counts group_id="E1" events="18" subjects_affected="15" subjects_at_risk="6848"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Typhus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="6848"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Urethritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="23" subjects_affected="22" subjects_at_risk="6848"/>
                <counts group_id="E2" events="17" subjects_affected="14" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Viral Infection</sub_title>
                <counts group_id="E1" events="35" subjects_affected="32" subjects_at_risk="6848"/>
                <counts group_id="E2" events="29" subjects_affected="29" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Viral Pharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Viral Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Viral Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Vulval Abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Wound Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accident</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Adverse Event Following Immunisation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Animal Bite</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6848"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Arthropod Bite</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Burns Second Degree</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Chemical Poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Chest Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Clavicle Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="6848"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Ear Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Electrical Burn</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Eye Injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Eyeball Rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Facial Bones Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="6848"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Femur Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Fibula Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Foot Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Forearm Fracture</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="6848"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Foreign Body</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Foreign Body In Eye</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Genital Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Gun Shot Wound</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Hand Fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Head Injury</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6848"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Humerus Fracture</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="6848"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Impacted Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Intentional Overdose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Joint Dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Joint Injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Ligament Sprain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Limb Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Lower Limb Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Multiple Fractures</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Multiple Injuries</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Muscle Strain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Near Drowning</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Open Wound</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Poisoning Deliberate</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Postoperative Adhesion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Postoperative Ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Radius Fracture</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6848"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Road Traffic Accident</sub_title>
                <counts group_id="E1" events="75" subjects_affected="71" subjects_at_risk="6848"/>
                <counts group_id="E2" events="39" subjects_affected="38" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Scrotal Haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Snake Bite</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Soft Tissue Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Sports Injury</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Stab Wound</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Tendon Rupture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Thermal Burn</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Tibia Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Toxicity To Various Agents</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Tracheal Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Traumatic Brain Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Traumatic Intracranial Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Upper Limb Fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6848"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Calcium Deficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone Cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Exostosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Fasciitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Fracture Malunion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Jaw Cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Muscle Spasms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Rheumatic Fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Synovial Cyst</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute Lymphocytic Leukaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Angiofibroma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Benign Neoplasm Of Skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Benign Soft Tissue Neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Bone Giant Cell Tumour Benign</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Bone Sarcoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Breast Neoplasm</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Ear Neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Fibroadenoma Of Breast</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Fibrous Histiocytoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Haemangioma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Lip Neoplasm Benign</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Lymphangioma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Skin Papilloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Soft Tissue Neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Teratoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Disseminated Encephalomyelitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Autonomic Neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Cerebral Venous Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Complex Partial Seizures</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6848"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Convulsions Local</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Encephalitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="6848"/>
                <counts group_id="E2" events="7" subjects_affected="4" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Extrapyramidal Disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Febrile Convulsion</sub_title>
                <counts group_id="E1" events="23" subjects_affected="13" subjects_at_risk="6848"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Grand Mal Convulsion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Guillain-Barre Syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Intercostal Neuralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Ischaemic Stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Migraine Without Aura</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Partial Seizures</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Status Epilepticus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Tension Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Tonic Convulsion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Viith Nerve Paralysis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion Complete</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Abortion Incomplete</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Abortion Spontaneous</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Abortion Spontaneous Incomplete</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Abortion Threatened</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Breech Presentation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Cephalo-Pelvic Disproportion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Eclampsia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Ectopic Pregnancy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>False Labour</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Foetal Distress Syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Oligohydramnios</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Postpartum Haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Premature Labour</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6848"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Puerperal Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Stillbirth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal Behaviour</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Acute Psychosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Bipolar I Disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Bipolar Disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Mental Disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Psychosomatic Disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Psychotic Disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6848"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Somatoform Disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Suicide Attempt</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus Ureteric</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Glomerulonephritis Acute</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Nephrotic Syndrome</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Neurogenic Bladder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Post Streptococcal Glomerulonephritis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="6848"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Renal Tubular Acidosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Acquired Phimosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Breast Mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Dysfunctional Uterine Bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Haemorrhagic Ovarian Cyst</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Ovarian Cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Ovarian Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Uterine Cervical Erosion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Uterine Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Vaginal Haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Adenoidal Hypertrophy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Asphyxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="19" subjects_affected="12" subjects_at_risk="6848"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Bronchial Hyperreactivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Nasal Polyps</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Nasal Septum Deviation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Neonatal Asphyxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Respiratory Acidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Sleep Apnoea Syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Inflammation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Dermal Cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Henoch-Schonlein Purpura</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Skin Hypertrophy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Child Abuse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Physical Assault</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Victim Of Child Abuse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Victim Of Crime</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Victim Of Sexual Abuse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abortion Induced</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aneurysm Ruptured</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDra 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="942" subjects_at_risk="1334"/>
                <counts group_id="E2" subjects_affected="453" subjects_at_risk="663"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="530" subjects_affected="378" subjects_at_risk="1334"/>
                <counts group_id="E2" events="244" subjects_affected="167" subjects_at_risk="663"/>
              </event>
              <event>
                <sub_title>Injection Site Erythema</sub_title>
                <counts group_id="E1" events="142" subjects_affected="107" subjects_at_risk="1334"/>
                <counts group_id="E2" events="71" subjects_affected="52" subjects_at_risk="663"/>
              </event>
              <event>
                <sub_title>Injection Site Pain</sub_title>
                <counts group_id="E1" events="994" subjects_affected="616" subjects_at_risk="1334"/>
                <counts group_id="E2" events="449" subjects_affected="275" subjects_at_risk="663"/>
              </event>
              <event>
                <sub_title>Injection Site Swelling</sub_title>
                <counts group_id="E1" events="84" subjects_affected="68" subjects_at_risk="1334"/>
                <counts group_id="E2" events="36" subjects_affected="33" subjects_at_risk="663"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="689" subjects_affected="476" subjects_at_risk="1334"/>
                <counts group_id="E2" events="352" subjects_affected="239" subjects_at_risk="663"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="291" subjects_affected="267" subjects_at_risk="1334"/>
                <counts group_id="E2" events="137" subjects_affected="125" subjects_at_risk="663"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="113" subjects_affected="85" subjects_at_risk="1334"/>
                <counts group_id="E2" events="61" subjects_affected="45" subjects_at_risk="663"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="104" subjects_affected="95" subjects_at_risk="1334"/>
                <counts group_id="E2" events="62" subjects_affected="54" subjects_at_risk="663"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="585" subjects_affected="414" subjects_at_risk="1334"/>
                <counts group_id="E2" events="296" subjects_affected="197" subjects_at_risk="663"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="866" subjects_affected="567" subjects_at_risk="1334"/>
                <counts group_id="E2" events="409" subjects_affected="264" subjects_at_risk="663"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="69" subjects_affected="63" subjects_at_risk="1334"/>
                <counts group_id="E2" events="61" subjects_affected="48" subjects_at_risk="663"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="48" subjects_affected="46" subjects_at_risk="1334"/>
                <counts group_id="E2" events="43" subjects_affected="36" subjects_at_risk="663"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Sanofi Pasteur Inc.</organization>
      <email>Contact-US@sanofi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

